Carol Lindstrom, a director of Genpact Limited (ticker G), reported a sale of 2,326 common shares on 08/12/2025 at $43.17 per share. After the disposition she beneficially owned 21,185 shares directly. The filing is limited to a single non-derivative sale and shows no option or derivative activity.
Genpact director Thimaya K. Subaiya received an award of unvested restricted share units (RSUs) under the Genpact Limited 2017 Omnibus Incentive Compensation Plan reported on 08/12/2025. Each RSU converts one-for-one into a common share and the filing shows the reporting person as beneficially owning 2,020 shares following the award. The RSUs fully vest on December 31, 2025 subject to continued service and will be settled in common shares on December 31, 2026. The Form 4 indicates a compensatory grant (price shown as $0) and was filed by a single reporting person.
Genpact Limited submitted a Form 144 notice for the proposed sale of 2,326 common shares, with an aggregate market value of $100,413.42. The shares represent a small fraction of the issuer's outstanding common stock (174,270,076 shares outstanding) and were acquired as restricted stock on 12/31/2019. The broker listed is Morgan Stanley Smith Barney LLC and the securities are designated for sale on the NYSE with an approximate sale date of 08/12/2025. The form indicates no securities sold in the past three months and includes the signer’s representation that they are not aware of undisclosed material adverse information about the issuer.
Genpact reported continued top-line and profit growth for the quarter ended June 30, 2025. Net revenue rose to $1.254 billion from $1.176 billion a year earlier, while net income increased to $133 million from $122 million, producing diluted EPS of $0.75 versus $0.67. Gross profit and operating income also increased, reflecting higher revenues partially offset by higher SG&A.
The balance sheet expanded: total assets grew to $5.308 billion and shareholders' equity to $2.587 billion. Cash and equivalents were $663 million. The company completed the acquisition of XponentL for total consideration of $159.8 million (including a $77.5 million contingent earn-out recognized at fair value), recording $111.9 million of goodwill and customer/marketing intangibles. Short-term borrowings and the current portion of long-term debt rose (current portion $375.7 million), and the allowance for credit losses on receivables increased to $26.8 million.
Genpact Ltd. (G) Form 3 filing reports that Thimaya K. Subaiya, listed at C/O Genpact LLC, 521 Fifth Avenue, New York, NY, filed an initial Section 16 statement relating to an event on 07/31/2025. The filing identifies Subaiya as a Director and indicates no securities are beneficially owned at the time of this statement. The form was signed by an attorney-in-fact on 08/08/2025.